Company profile: Coeur
1.1 - Company Overview
Company description
- Provider of disposable medical products used in diagnostic imaging and other medical procedures, offering design, manufacturing, and assembly services. A state-of-the-art designer and contract manufacturer for medical and commercial markets, with manufacturing and assembly operations in North Carolina and Wisconsin, and providing regulatory support.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Coeur
OnDosis
HQ: Sweden
Website
- Description: Provider of flexible, individualized dosing of oral medicines via a Dosage Manager delivering micro-unit forms (granules, pellets, mini-tablets) with accurate dosing, plus connected services: patient app, cloud platform, and physician interface for remote monitoring, adherence support, physician-patient communication, secure data exchange, regulatory compliance, and third-party integrations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnDosis company profile →
Xeris Biopharma
HQ: United States
Website
- Description: Provider of pharmaceutical therapies in endocrinology, neurology, and gastroenterology, including Gvoke and Ogluo ready-to-use glucagon injections for severe hypoglycemia; Keveyis, the first FDA-approved treatment for Primary Periodic Paralysis; Recorlev for endogenous Cushing's syndrome; and levothyroxine for hypothyroidism. Ogluo is marketed in the UK/EU under an exclusive agreement with Tetris Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xeris Biopharma company profile →
Acorda Therapeutics
HQ: United States
Website
- Description: Provider of commercial-stage biopharmaceutical therapies, identifying, developing and commercializing therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other nervous system disorders. Products include INBRIJA (levodopa inhalation powder for Parkinson’s symptoms), AMPYRA (dalfampridine to improve walking in adults with MS), and the ARCUS drug delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acorda Therapeutics company profile →
PLx Pharma
HQ: United States
Website
- Description: Provider of non-steroidal anti-inflammatory drugs for prescription and over-the-counter markets, developing and commercializing these therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PLx Pharma company profile →
Elucida Oncology
HQ: United States
Website
- Description: Provider of targeted C'Dot Drug Conjugates (CDCs) for patients with primary solid tumor and metastatic cancer. Ultra-small CDC nanoparticles penetrate tumors, carry high drug payloads, and clear rapidly via kidneys (Target or Clear) to reduce systemic exposure and off-target toxicity. Pipeline includes ELU001, a CDC targeting folate receptor alpha in clinical trials; ELU002; and surface chemistry for toxic payloads and radionuclides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elucida Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Coeur
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Coeur
2.2 - Growth funds investing in similar companies to Coeur
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Coeur
4.2 - Public trading comparable groups for Coeur
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →